Related Experiment Video
Updated: Nov 16, 2025

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
Published on: May 12, 2023
Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis
Li Shi1, Jie Xu1, Wenwei Xiao1
1Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, People's Republic of China.
Insights
Asthma prevalence in COVID-19 patients mirrors the general population. Asthma may protect against COVID-19 mortality, warranting attention for co-infected individuals.
Area of Science:
- Pulmonology
- Infectious Diseases
- Epidemiology
Background:
- The impact of asthma on contracting coronavirus disease 2019 (COVID-19) or experiencing severe outcomes remains unclear.
- Investigating the relationship between asthma and COVID-19 outcomes is crucial for patient management.
Purpose of the Study:
- To determine the prevalence of asthma among COVID-19 patients.
- To analyze the association between asthma and adverse outcomes in COVID-19 patients.
Main Methods:
- A meta-analysis was conducted using data from 116 articles (119 studies) encompassing 403,392 COVID-19 cases.
- Pooled prevalence and effect sizes (ES) were calculated to assess the association between asthma and COVID-19 outcomes.
Main Results:
- The global pooled prevalence of asthma in COVID-19 patients was 8.3% (95% CI, 7.6-9.0).
- Unadjusted analyses showed no significant association between asthma and reduced risk of poor outcomes or mortality.
- Adjusted analyses indicated that asthma is significantly associated with a reduced risk of mortality in COVID-19 patients (ES 0.80, 95% CI 0.74-0.86).
Conclusions:
- Asthma prevalence in COVID-19 patients is comparable to the general population.
- Asthma may act as an independent protective factor against COVID-19 mortality.
- Further research is needed to confirm these findings and guide tailored interventions for co-infected patients.
Background:
It is unclear whether asthma has an influence on contracting coronavirus disease 2019 (COVID-19) or having worse outcomes from COVID-19 disease.
Objective:
To explore the prevalence of asthma in patients with COVID-19 and the relationship between asthma and patients with COVID-19 with poor outcomes.
Methods:
The pooled prevalence of asthma in patients with COVID-19 and corresponding 95% confidence interval (CI) were estimated. The pooled effect size (ES) was used to evaluate the association between asthma and patients with COVID-19 with poor outcomes.
Results:
The pooled prevalence of asthma in patients with COVID-19 worldwide was 8.3% (95% CI, 7.6-9.0) based on 116 articles (119 studies) with 403,392 cases. The pooled ES based on unadjusted effect estimates revealed that asthma was not associated with reduced risk of poor outcomes in patients with COVID-19 (ES, 0.91; 95% CI, 0.78-1.06). Similarly, the pooled ES based on unadjusted effect estimates revealed that asthma was not associated with the reduced risk of mortality in patients with COVID-19 (ES, 0.88; 95% CI, 0.73-1.05). However, the pooled ES based on adjusted effect estimates indicated that asthma was significantly associated with reduced risk of mortality in patients with COVID-19 (ES 0.80, 95% CI 0.74-0.86).
Conclusion:
The pooled prevalence of asthma in patients with COVID-19 was similar to that in the general population, and asthma might be an independent protective factor for the death of patients with COVID-19, which suggests that we should pay high attention to patients co-infected asthma and COVID-19 and take locally tailored interventions and treatment. Further well-designed studies with large sample sizes are required to verify our findings.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Nursing Management
First, in...
Asthma-I: Introduction

